Cargando…
Opioid Antagonists from the Orvinol Series as Potential Reversal Agents for Opioid Overdose
[Image: see text] The opioid crisis continues to claim many lives, with a particular issue being the ready availability and use (whether intentional or accidental) of fentanyl and fentanyl analogues. Fentanyl is both potent and longer-acting than naloxone, the standard of care for overdose reversal,...
Autores principales: | Disney, Alex, Olson, Keith M., Shafer, Amanda M., Moore, Sierra C., Anand, Jessica P., Traynor, John R., Husbands, Stephen M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634796/ https://www.ncbi.nlm.nih.gov/pubmed/36223082 http://dx.doi.org/10.1021/acschemneuro.2c00464 |
Ejemplares similares
-
Orvinols
with Mixed Kappa/Mu Opioid Receptor Agonist
Activity
por: Greedy, Benjamin M., et al.
Publicado: (2013) -
C7β-Methyl
Analogues of the Orvinols: The Discovery
of Kappa Opioid Antagonists with Nociceptin/Orphanin FQ Peptide (NOP)
Receptor Partial Agonism and Low, or Zero, Efficacy at Mu Opioid Receptors
por: Cueva, Juan Pablo, et al.
Publicado: (2015) -
Treating Non-fentanyl-derived Synthetic Opioid Overdose with a Traditional Opioid Reversal Agent
por: Acuna, Valerie S, et al.
Publicado: (2020) -
Targeting opioid receptor signaling in depression: do we need selective κ opioid receptor antagonists?
por: Bailey, Sarah J., et al.
Publicado: (2018) -
Fumaroylamino-4,5-epoxymorphinans
and Related Opioids
with Irreversible μ Opioid Receptor Antagonist Effects
por: Moynihan, Humphrey A., et al.
Publicado: (2012)